Silk Road Medical (SILK) Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SILK shares.
View SILK analyst ratings or view top-rated stocks.

5 brokerages have issued 1 year price targets for Silk Road Medical's stock. Their SILK share price forecasts range from $27.00 to $60.00. On average, they predict the company's stock price to reach $48.25 in the next twelve months. This suggests a possible upside of 51.0% from the stock's current price.
View analysts price targets for SILK or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $52.85 at the beginning of 2023. Since then, SILK shares have decreased by 39.5% and is now trading at $31.95.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 25th 2023.
View our SILK earnings forecast.

Silk Road Medical, Inc (NASDAQ:SILK) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.04. The firm had revenue of $40.13 million for the quarter, compared to the consensus estimate of $40.69 million. Silk Road Medical had a negative net margin of 36.47% and a negative trailing twelve-month return on equity of 50.13%. The firm's revenue for the quarter was up 43.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.48) EPS.

ETFs with the largest weight of Silk Road Medical (NASDAQ:SILK) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), American CenturyFocused Dynamic Growth ETF (FDG), Hypatia Women CEO ETF (WCEO), Invesco Nasdaq Future Gen 200 ETF (QQQS), First Trust Small Cap Growth AlphaDEX Fund (FYC), Global X Aging Population ETF (AGNG), Principal Healthcare Innovators ETF (BTEC) and Principal U.S. Small-Cap Multi-Factor ETF (PSC).

Silk Road Medical issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $176.00 million-$184.00 million, compared to the consensus revenue estimate of $180.27 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an initial public offering (IPO) on Thursday, April 4th 2019. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (8.38%), BlackRock Inc. (6.93%), Clearbridge Investments LLC (4.46%), Kayne Anderson Rudnick Investment Management LLC (3.54%), American Century Companies Inc. (3.51%) and Fred Alger Management LLC (2.64%). Insiders that own company stock include Andrew S Davis, Andrew S Davis, Elizabeth H Weatherman, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Richard Ruedy and Tony M Chou.
View institutional ownership trends.

Shares of SILK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $31.95.

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $1.24 billion and generates $138.64 million in revenue each year. The company earns $-55,010,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

The company employs 352 workers across the globe.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for the company is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at investors@silkroadmed.com, or via fax at 408-720-9013.